ERBB2 and heart failure: One year later, after a full recovery from heart failure, because of disease progression, and with consideration of the clinical benefits from anti-HER2 treatment and the absence of absolute cardiologic contraindications (LVEF was significantly improved with proper treatment), therapy with full dose trastuzumab was resumed along with a close monitoring program of left ventricular function for about two years without any further cardiovascular complications.